GLP-1 receptor agonists beyond diabetes management
2024
GLP-1 Receptor Agonists: Expanding Their Use Beyond Diabetes
Editorial
Conclusion
GLP-1 receptor agonists have significant benefits for diabetes management and obesity treatment, but accessibility and safety concerns need to be addressed.
Supporting Evidence
- GLP-1 receptor agonists have shown cardiovascular risk reduction in landmark trials.
- Semaglutide has been effective for weight loss and has cardiovascular benefits.
- GLP-1 RAs are now approved for obesity treatment in individuals without diabetes.
- Adverse effects include gastrointestinal reactions, which can lead to severe complications.
- High costs and limited availability create barriers to access for eligible patients.
Takeaway
GLP-1 medications help people with diabetes and obesity, but they can be hard to get and might cause some side effects.
Potential Biases
Potential underreporting of adverse effects due to off-label use and lack of robust safety data.
Limitations
Concerns about adverse effects and accessibility issues, especially for off-label use and in low-income countries.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website